[{"id":"897414a3-bc36-4d90-b0c6-902256e6b2d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02334865","created_at":"2021-02-24T21:53:04.763Z","updated_at":"2025-02-25T14:35:10.773Z","phase":"Phase 1","brief_title":"SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy","source_id_and_acronym":"NCT02334865","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 09/16/2022","primary_completion_date":" 09/16/2022","study_txt":" Completion: 05/19/2026","study_completion_date":" 05/19/2026","last_update_posted":"2024-06-04"},{"id":"06d3177e-5a92-47e8-850d-071f514b294e","acronym":"SURVIVE","url":"https://clinicaltrials.gov/study/NCT05163080","created_at":"2021-12-20T16:53:58.249Z","updated_at":"2024-07-02T16:35:17.754Z","phase":"Phase 2","brief_title":"SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)","source_id_and_acronym":"NCT05163080 - SURVIVE","lead_sponsor":"MimiVax, LLC","biomarkers":" IDH1 • MGMT • CD8","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1 • MGMT • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 08/18/2024","primary_completion_date":" 08/18/2024","study_txt":" Completion: 08/18/2024","study_completion_date":" 08/18/2024","last_update_posted":"2024-02-26"},{"id":"8b53a2b0-726f-488a-ad4e-487b5d2d48cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895761","created_at":"2021-05-20T11:54:08.701Z","updated_at":"2024-07-02T16:35:22.223Z","phase":"Phase 1","brief_title":"Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer","source_id_and_acronym":"NCT04895761","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • letrozole • maveropepimut-S (MVP-S)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/10/2021","start_date":" 09/10/2021","primary_txt":" Primary completion: 06/16/2023","primary_completion_date":" 06/16/2023","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-01-25"},{"id":"6f412c81-9eb0-48e7-8b40-e0e8b91d12d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05582590","created_at":"2022-10-17T13:56:01.481Z","updated_at":"2024-07-02T16:35:23.356Z","phase":"Phase 1","brief_title":"Autologous T Cells Targeting HPV16 HPV18 \u0026 Survivin in Patients With R/R HPV-related Oropharyngeal Cancers","source_id_and_acronym":"NCT05582590","lead_sponsor":"NexImmune Inc.","biomarkers":" HLA-A","pipe":"","alterations":" ","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NEXI-003"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 08/25/2027","study_completion_date":" 08/25/2027","last_update_posted":"2024-01-15"},{"id":"5299d983-b5a6-4139-a880-c383cdcdadb8","acronym":"SPiReL","url":"https://clinicaltrials.gov/study/NCT03349450","created_at":"2021-01-18T16:32:24.143Z","updated_at":"2025-02-25T16:07:12.338Z","phase":"Phase 2","brief_title":"DPX-Survivac and Checkpoint Inhibitor in DLBCL","source_id_and_acronym":"NCT03349450 - SPiReL","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/13/2018","start_date":" 03/13/2018","primary_txt":" Primary completion: 10/31/2021","primary_completion_date":" 10/31/2021","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-11-02"},{"id":"d41013a9-659b-4bd4-843d-44f12482f427","acronym":"STELLA","url":"https://clinicaltrials.gov/study/NCT02475707","created_at":"2021-01-18T11:55:12.467Z","updated_at":"2024-07-02T16:35:31.622Z","phase":"Phase 1","brief_title":"Administration of Donor MultiTAA-Specific T Cells for ALL","source_id_and_acronym":"NCT02475707 - STELLA","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD8 • CD4 • MME","pipe":"","alterations":" ","tags":["CD8 • CD4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 10/29/2019","primary_completion_date":" 10/29/2019","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-26"},{"id":"4c345493-ab62-410a-b773-a42c655f0249","acronym":"PDC-LUNG-101","url":"https://clinicaltrials.gov/study/NCT03970746","created_at":"2021-01-18T19:31:48.798Z","updated_at":"2024-07-02T16:35:31.964Z","phase":"Phase 1/2","brief_title":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","source_id_and_acronym":"NCT03970746 - PDC-LUNG-101","lead_sponsor":"PDC*line Pharma SAS","biomarkers":" CD8 • HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["CD8 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed • PDC*lung"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 09/10/2019","start_date":" 09/10/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-24"},{"id":"9eac4268-8e45-4c25-be18-2972151ca188","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494167","created_at":"2021-01-18T12:01:22.240Z","updated_at":"2024-07-02T16:35:45.346Z","phase":"Phase 1","brief_title":"Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)","source_id_and_acronym":"NCT02494167","lead_sponsor":"Baylor College of Medicine","biomarkers":" KIT • WT1 • CD33 • ANPEP","pipe":"","alterations":" ","tags":["KIT • WT1 • CD33 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-06-19"},{"id":"39fb3a40-1da6-4a5f-a51a-d270235ef673","acronym":"VITALIZE","url":"https://clinicaltrials.gov/study/NCT04920617","created_at":"2021-06-11T00:54:35.677Z","updated_at":"2025-02-25T16:16:21.527Z","phase":"Phase 2b","brief_title":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04920617 - VITALIZE","lead_sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S)"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/18/2021","start_date":" 06/18/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-04-07"},{"id":"50d581ad-944c-4ed3-86ce-7d1ac402d2ae","acronym":"PC002-01","url":"https://clinicaltrials.gov/study/NCT05263583","created_at":"2022-03-02T16:52:44.847Z","updated_at":"2024-07-02T16:35:58.906Z","phase":"Phase 2","brief_title":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma","source_id_and_acronym":"NCT05263583 - PC002-01","lead_sponsor":"Cothera Bioscience, Inc","biomarkers":" MYC • BCL2","pipe":"","alterations":" ","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sepantronium bromide (PC-002)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/09/2022","start_date":" 12/09/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2022-12-19"},{"id":"7d618474-6245-4ce7-a481-a42d155c55d0","acronym":"KEYNOTE 903","url":"https://clinicaltrials.gov/study/NCT03836352","created_at":"2021-01-17T17:21:32.990Z","updated_at":"2025-02-25T16:08:54.319Z","phase":"Phase 2","brief_title":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide \u0026 Pembrolizumab, in Subjects With Selected Advanced \u0026 Recurrent Solid Tumors","source_id_and_acronym":"NCT03836352 - KEYNOTE 903","lead_sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-03-31"},{"id":"4344444c-75d7-40a8-8d13-8d1190b703c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00620321","created_at":"2021-01-18T02:18:20.529Z","updated_at":"2024-07-02T16:36:55.902Z","phase":"Phase 2","brief_title":"A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT00620321","lead_sponsor":"Eli Lilly and Company","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • gataparsen (LY2181308)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 01/01/2010","primary_completion_date":" 01/01/2010","study_txt":" Completion: 01/01/2010","study_completion_date":" 01/01/2010","last_update_posted":"2019-09-09"},{"id":"b35e4385-5542-41cd-ab43-a9571f86de15","acronym":"","url":"https://clinicaltrials.gov/study/NCT01416038","created_at":"2021-01-18T05:49:49.052Z","updated_at":"2024-07-02T16:37:23.200Z","phase":"Phase 1","brief_title":"Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer","source_id_and_acronym":"NCT01416038","lead_sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","biomarkers":" BIRC5","pipe":"","alterations":" ","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • maveropepimut-S (MVP-S)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2017-04-21"},{"id":"31ad4fb0-d303-4eae-8d17-c8dff89eabb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01250470","created_at":"2021-01-18T05:02:20.108Z","updated_at":"2024-07-02T16:37:24.983Z","phase":"Phase 1","brief_title":"Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma","source_id_and_acronym":"NCT01250470","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG","pipe":" | ","alterations":" BIRC5 expression","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 09/05/2012","start_date":" 09/05/2012","primary_txt":" Primary completion: 05/29/2014","primary_completion_date":" 05/29/2014","study_txt":" Completion: 05/29/2014","study_completion_date":" 05/29/2014","last_update_posted":"2017-02-27"}]